ProMIS Neurosciences (PMN) director purchases 2,000 common shares in open market

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. director Williams Eugene reported an open-market purchase of company stock. He bought 2,000 Common Shares at a price of $24.40 per share, increasing his direct holdings to 12,397 Common Shares following the transaction.

Insider Trade Summary

Net Buyer: 2,000 shares ($48,800)

Net Buy 1 txn

Insider Williams Eugene

Role Director

Bought 2,000 shs ($49K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	2,000	$24.40	$49K

Holdings After Transaction: Common Shares — 12,397 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Eugene

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/05/2026		P		2,000	A	$24.4	12,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Max A. Milbury, Attorney in Fact for Eugene Williams	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report on Form 4?

ProMIS Neurosciences reported that director Williams Eugene bought 2,000 Common Shares in an open-market transaction at $24.40 per share. This insider purchase increased his directly held stake in the company’s stock to a total of 12,397 Common Shares after the transaction.

How many ProMIS Neurosciences (PMN) shares did the director buy and at what price?

Director Williams Eugene purchased 2,000 Common Shares of ProMIS Neurosciences at $24.40 per share. The filing characterizes this as an open-market purchase, meaning he acquired the shares on the market rather than through an option exercise or similar equity award.

What is Williams Eugene’s total ProMIS Neurosciences (PMN) ownership after this trade?

After the reported transaction, director Williams Eugene directly owns 12,397 Common Shares of ProMIS Neurosciences. The Form 4 notes that these shares are held with direct ownership, reflecting the increase from his purchase of 2,000 additional shares in the open market.

Was the ProMIS Neurosciences (PMN) insider trade a purchase or a sale?

The ProMIS Neurosciences Form 4 discloses a purchase, not a sale. Director Williams Eugene completed an open-market buy of 2,000 Common Shares at $24.40 per share, resulting in a net increase of 2,000 shares in his directly owned position.

What type of security did the ProMIS Neurosciences (PMN) director trade?

The director traded ProMIS Neurosciences Common Shares. The Form 4 specifies that the transaction involved non-derivative Common Shares, acquired through an open-market purchase, rather than options, warrants, or other derivative securities linked to the company’s stock.